Endometriosis, Endometriosis Fertility, Endometriosis-related Pain
Conditions
Keywords
endometriosis, miRNA
Brief summary
We therefore propose a research project based on the prospective evaluation of miRNAs (blood and salivary) in patients with endometriosis diagnosed (by clinical examination and imaging) or suspected of endometriosis (clinical/radiological discordance) and in need of management in routine care (surgical or medical PMA) in the Endometriosis Expert Center Hospital.
Interventions
OTHERBlood and salivar test
Saliva samples will be taken (concomitant with a visit carried out as part of routine care): * At the pre-therapy visit (t3), * At the post-treatment visit (at 3-6 weeks). Blood samples will be taken at two stages (concomitant with a blood test performed as part of routine care): * At the pre-therapy visit (t3), * At the post-treatment visit (at 3-6 weeks).
Sponsors
Groupe expert en endometriose-6 centre expert en endometriose
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 43 Years
Inclusion criteria
\- Patient aged 18 to 43 years old, * Patient has dated and signed the consent form, * Patient affiliated with the French health care system, * Patients with formal endometriosis diagnosed by clinical examination and imaging or suspicion of endometriosis for which the diagnosis is a source of discrepancy between clinical and radiological data, * Patient with an indication for medically assisted procreation (MAP) or surgery validated in CPR (in routine care), * Patient who has had a pelvic MRI, * Patient who completed the symptom and quality of life questionnaires
Exclusion criteria
* Pregnant patient, * Patient infected with the human immunodeficiency virus (HIV), * Patient with significant difficulties in reading or writing the French language, * Patient with a personal history of cancer, * Patient unable to comply with study and/or follow-up procedures, * Patient who has objected to the collection of her data. * Patient participating in another clinical research study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Describe the evolution of miRNA expression (blood and salivary) | 1 month |
Secondary
| Measure | Time frame |
|---|---|
| To quantify the reproducibility of salivary miRNA expression over time (between the inclusion visit and the pre-therapy visit) ; | 1 month |
| To describe (quantitatively and qualitatively) the expression of blood and salivary miRNAs in patients with suspected or actual endometriosis; | 1 time |
| Describe the expression of miRNAs (blood and salivary) according to the presence or absence of endometriosis and according to the endometriosis phenotype ; | 1 time |
| Describe the relationship between miRNA expression (blood and salivary) and the level of ovarian reserve, as estimated by the AMH assay in patients of childbearing age ; | 1 time |
Countries
France
Contacts
Primary ContactSOFIANE BENDIFALLAH, MD PHD
Backup ContactEMILE DARAI, Prof
Outcome results
None listed